MAPT and breast carcinoma: Knockdown of MAPT-AS1 markedly decreased the expression of TAU, thereby inhibiting the assembly of tubulin dimers into microtubules and microtentacle formation, and weakening its ability to compete against paclitaxel, finally inhibited the proliferation and migration and sensitizes the breast cancer cells to paclitaxel.